Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Publication | Closed Access

DOI

480

Citations

References

2008

Year

Daniel D. Mikol, Frederik Barkhof, Peter Chang, Patricia K. Coyle, Douglas Jeffery, Steven R. Schwid, Bettina Stubinski, Bernard M.J. Uitdehaag

The Lancet Neurology

Autoimmune DiseaseDisease ProgressionNeurological DisorderMedicineSubcutaneous InterferonImmunologyClinical TrialsNeurologyMultiple SclerosisNeuroimmunologyGlatiramer Acetate